Medicine
Bridging Anticoagulation for Atrial Fibrillation Procedures
Quick fact
Routine bridging with heparin for patients on warfarin undergoing procedures is not beneficial; it increases major bleeding risk without reducing thromboembolism, except in patients at high risk for stroke.
Why this is interesting
You're about to have surgery, but you take warfarin for atrial fibrillation. Your doctor tells you to stop it—but what if you could stay protected with a 'bridge'? That bridge might actually cause more harm than good.
Read the full explanation
Understanding Bridging Anticoagulation for Atrial Fibrillation Procedures
Imagine your blood as a river that normally flows freely. Warfarin makes that river sluggish, reducing the chance of forming a clot that could cause a stroke. But surgery needs a river that can clot quickly to stop bleeding. So you stop warfarin a few days before the procedure. The problem is that during those days, you lose protection. Bridging means using a short-acting blood thinner called heparin to keep the river slow until just before the operation, then stopping it so the surgeon can operate safely. After the procedure, the bridge is restarted until the warfarin kicks back in. In practice, this is done with injections of low-molecular-weight heparin (like enoxaparin) that the patient can self-administer.
A deeper explanation
The mechanism behind bridging is that heparin has a much shorter half-life (about 4-6 hours) compared to warfarin (~40 hours), and its effect can be reversed quickly. This allows near-continuous anticoagulation until the very last moment before surgery. However, this constant anticoagulation also increases the risk of bleeding at the surgical site. The decision hinges on the balance: if the patient's risk of stroke without anticoagulation (estimated by CHADS2 score) is low, the tiny benefit of bridging is outweighed by the significant bleeding risk. For high-risk patients (e.g., mechanical heart valve, recent stroke), bridging reduces thromboembolic events enough to justify the bleeding risk. Guidelines from major societies now recommend bridging only in carefully selected high-risk patients, and discourage routine bridging for most.